This is a phase III multi-centre study in two periods: the first period is a phosphate binder and lipid lowering drugs washout for 8 weeks, the second period is a double-blind, randomised, parallel group, fixed dose, for 12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
642
The Change in Serum Phosphorus
The change from baseline to week 12
Time frame: 12 weeks
The Change in LDL-cholesterol
The percentage change from baseline to week 12
Time frame: 12 weeks
The Change in Total-cholesterol
Time frame: 12 weeks
The Change in HDL-cholesterol
Time frame: 12 weeks
The Change in Triglycerides
Time frame: 12 weeks
The Change in PTH
Time frame: 12 weeks
The Change in Ca
Time frame: 12 weeks
The Change in Ca x P Ion Product
Time frame: 12 weeks
The Incidence of Adverse Events
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Ajka, Hungary
Unnamed facility
Baja, Hungary
Unnamed facility
Budapest, Hungary
Unnamed facility
Esztergom, Hungary
Unnamed facility
Győr, Hungary
Unnamed facility
Hatvan, Hungary
Unnamed facility
Kisvárda, Hungary
Unnamed facility
Lecco, Italy
Unnamed facility
Modena, Italy
Unnamed facility
Pavia, Italy
...and 63 more locations